ArticleSchizophrenia research2008
In vitro and in vivo demonstration of risperidone implants in mice.
Article in Schizophrenia research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism.Nature chemistry · 2025Article
- Differences between criminal offender versus non-offender female patients with schizophrenia spectrum disorder: a retrospective cohort study.Archives of women's mental health · 2025Article
- Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art.Journal of nanobiotechnology · 2023Review
- 3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs.Drug delivery · 2022Article
- A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery.International journal of pharmaceutics: X · 2021Article
- Development of a Biodegradable Subcutaneous Implant for Prolonged Drug Delivery Using 3D Printing.Pharmaceutics · 2020Article
- Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications.Polymers · 2018Review
- Poly(lactic-co-glycolic acid) devices: Production and applications for sustained protein delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018Review
- Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD).Drug delivery and translational research · 2018Article
- Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer.Drug delivery and translational research · 2018Article
- A method to slow down the ionization-dependent release of risperidone loaded in a thermoresponsive poly(N-acryloyl glycinamide) hydrogel.Drug delivery and translational research · 2017Article
- The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Therapeutic advances in psychopharmacology · 2014Review
- Drug-eluting nasal implants: formulation, characterization, clinical applications and challenges.Pharmaceutics · 2014Article
- Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies.Journal of advanced pharmaceutical technology & research · 2014Article
- A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity.The Journal of pharmacy and pharmacology · 2013Article
- Long-acting injectable antipsychotics in first-episode schizophrenia.Schizophrenia research and treatment · 2012Article
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.Polymers · 2011Article
- In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.Pharmaceutical research · 2010Article
- A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process.Journal of biomedical materials research. Part B, Applied biomaterials · 2010Article
- Development of a novel 3-month drug releasing risperidone microspheres.Journal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNon-adherence with medication is a critical limitation in current long-term treatment of schizophrenia and a primary factor in poor quality-of-life outcomes. However, few treatments have addressed this shortcoming using an implantable drug delivery approach. The goal of this study was to provide in vitro and in vivo proof of concept for a long-term implantable risperidone delivery system in mice.
methodsImplantable formulations of risperidone were created using the biodegradable polymer Poly Lactic co Glycolic Acid (PLGA) combined with various drug loads. Implant bioactivity was tested using in vitro release and stability studies, as well as in vivo pharmacokinetic and behavioral studies in mice.
resultsThe pattern of risperidone release is influenced by various parameters, including polymer composition and drug load. In vitro measures demonstrate that risperidone is stable in implants under physiological conditions. Behavioral measures demonstrate the bioactivity of risperidone implants delivering 3 mg/kg/day in mice, while pharmacokinetic analyses indicate that reversibility is maintained throughout the delivery interval.
conclusionsThe current report suggests that implantable formulations are a viable approach to providing long-term delivery of antipsychotic medications based on in vivo animal studies and pharmacokinetics. Implantable medications demonstrated here can last two months or longer while maintaining coherence and removability past full release, suggesting a potential paradigm shift in the long-term treatment of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.